841302-36-1

Basic information

• Product Name: 2-Azabicyclo[3.1.0]hexane-2-carboxylic acid, phenylmethyl ester
• Synonyms: N-Cbz-2,3-methanopyrrolidine
• CAS NO: 841302-36-1
• Molecular Formula: C13H15NO2
• Molecular Weight: 217.268
• Mol File: 841302-36-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Azabicyclo[3.1.0]hexane-2-carboxylic acid, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Azabicyclo[3.1.0]hexane-2-carboxylic acid, phenylmethyl ester(841302-36-1)
• EPA Substance Registry System: 2-Azabicyclo[3.1.0]hexane-2-carboxylic acid, phenylmethyl ester(841302-36-1)

Safety Data

• Hazardous Substances Data: 841302-36-1(Hazardous Substances Data)

Usage

Structure

Bicyclic structure

Applications

Precursor in the synthesis of various drugs and organic compounds
Building block in the synthesis of chiral compounds
Therapeutic agent for neurological and psychiatric disorders
Starting material for the synthesis of diverse heterocyclic compounds
Valuable intermediate for chemical synthesis and drug development

Upstream product

• 593-71-5 Chloroiodomethane 
• 68471-57-8 2,3-dihydro-pyrrole-1-carboxylic acid benzyl ester 
• 25070-74-0 1-benzyloxycarbonylpyrrolidine 

Downstream Products

• 841302-37-2 (1RS,5SR)-2-azabicyclo[3.1.0]hexane hydrochloride 

Relevant articles and documents

5-Substituted indole-2-carboxamide derivatives

The present invention relates to compounds of formula I wherein R1 to R4 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention o

ADAMANTYGLYCINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS

Compounds are provided having the formula (I) [Chemical Structure] wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n + m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.